Personalized Gene Therapy Treatments for Cancer Market By Therapy Type (Gene Editing Therapies, Gene Insertion Therapies), By Application (Solid Tumors, Hematological Malignancies), By End-User (Hospitals, Research Institutions, Biotech and Pharma Companies), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Personalized Gene Therapy Treatments for Cancer Market was valued at USD 5.7 billion in 2024-e and will surpass USD 9.1 billion by 2030; growing at a CAGR of 8.0% during 2025 - 2030.

The personalized gene therapy treatments for cancer market is evolving rapidly, driven by advancements in gene editing and insertion technologies, which offer new opportunities for more targeted and effective cancer therapies. Gene therapy is revolutionizing the way cancer is treated by enabling more precise alterations at the genetic level, allowing treatments to be tailored to an individual’s unique genetic makeup. This approach offers the potential to not only treat cancer but also prevent its recurrence, offering hope for patients with types of cancer that were previously resistant to conventional therapies. Personalized gene therapies are especially promising in the treatment of both solid tumors and hematological malignancies, where traditional chemotherapy and radiation have had limited success.

The market is experiencing rapid growth as new gene-editing techniques, such as CRISPR, and gene insertion therapies are demonstrating significant potential in clinical trials. As personalized medicine becomes more mainstream, the demand for personalized gene therapies in oncology is expected to grow significantly. Increasing investment from biotechnology and pharmaceutical companies, along with stronger regulatory support, is further fueling the development of these innovative treatments. The ability to deliver tailored therapies that are designed to work with an individual’s genetic profile is transforming the cancer treatment landscape, leading to more effective and less toxic therapies.

Gene Editing Therapies Therapy Type is Largest Owing to Precision and Effectiveness

Gene editing therapies are the largest therapy type in the personalized gene therapy treatments for cancer market owing to their precision and effectiveness in targeting specific genetic mutations associated with cancer. Gene editing techniques, such as CRISPR, allow for the precise modification of the DNA of cancer cells, enabling the correction of genetic defects that drive tumor growth. By targeting specific mutations, gene editing therapies can significantly reduce the risk of side effects commonly associated with traditional cancer treatments, such as chemotherapy or radiation. This precision also increases the likelihood of successful outcomes and long-term remission for cancer patients.

Gene editing therapies have shown promise in treating various cancers, including those caused by genetic mutations, such as certain types of leukemia or lung cancer. These therapies allow for the modification of the patient’s own cells, which are then reintroduced into the body to target and kill cancer cells. As clinical trials continue to demonstrate the efficacy of gene editing in treating cancer, this segment is expected to remain the largest in the personalized gene therapy treatments for cancer market, with increasing adoption in both research and clinical settings.

Solid Tumors Application is Largest Owing to High Prevalence and Treatment Challenges

The solid tumors application is the largest in the personalized gene therapy treatments for cancer market owing to the high prevalence of solid tumors and the significant challenges in their treatment. Solid tumors, such as those found in the breast, lung, prostate, and colon, account for a large proportion of all cancer diagnoses. These tumors are often difficult to treat with traditional therapies due to their complex structure, the presence of drug-resistant cells, and their ability to metastasize to other parts of the body. Personalized gene therapies offer the potential to directly target the genetic mutations driving the growth of solid tumors, leading to more effective and precise treatments.

The ability to modify cancer cells at the genetic level, coupled with the possibility of tailoring treatments based on the unique genetic profile of a tumor, is revolutionizing the treatment of solid tumors. As advancements in gene editing and insertion techniques continue to evolve, the application of personalized gene therapies for solid tumors is expected to become more widespread, offering patients new treatment options and improved outcomes. This segment is set to remain the largest focus for personalized gene therapy developments in the market.

Biotech and Pharma Companies End-User Segment is Fastest Growing Owing to Investment in R&D

The biotech and pharma companies end-user segment is the fastest growing in the personalized gene therapy treatments for cancer market owing to their significant investment in research and development. Biotechnology and pharmaceutical companies are the key drivers of innovation in this space, as they are leading the charge in the development, commercialization, and distribution of personalized gene therapies for cancer. These companies have the resources and expertise to carry out extensive research, clinical trials, and regulatory approvals, which are essential for bringing personalized therapies to market.

With the increasing demand for more effective cancer treatments, biotech and pharma companies are focusing heavily on gene therapy research to provide targeted solutions that cater to the specific genetic profiles of cancer patients. The rapid growth of personalized medicine and the shift towards precision oncology are accelerating the involvement of biotech and pharmaceutical companies in this sector. As the market for personalized cancer therapies expands, biotech and pharma companies will continue to play a central role in shaping the future of cancer treatment.

Hematological Malignancies Application is Fastest Growing Owing to Breakthroughs in Gene Therapy

The hematological malignancies application is the fastest growing in the personalized gene therapy treatments for cancer market owing to breakthroughs in gene therapy and cell-based therapies. Hematological cancers, including leukemia, lymphoma, and myeloma, affect the blood, bone marrow, and lymphatic system. These cancers are often more challenging to treat with conventional therapies, as they involve the immune system and blood cells, which are difficult to target with traditional approaches. Personalized gene therapies, particularly gene editing and gene insertion techniques, offer the ability to modify the patient’s own immune cells to target and destroy cancer cells with higher precision.

Recent advances in CAR-T cell therapies, which use gene editing to modify T-cells to attack cancer cells, have shown remarkable success in treating hematological malignancies, particularly in leukemia and lymphoma. This success has driven the rapid growth of this application within the personalized gene therapy market, as more clinical trials and treatments are developed for hematological cancers. With the continuous advancement of gene therapy technologies and growing success rates, the hematological malignancies application is poised for further growth in the market.

North America Region is Largest Owing to Strong Healthcare Infrastructure and Innovation

North America is the largest region in the personalized gene therapy treatments for cancer market owing to its strong healthcare infrastructure, advanced medical research capabilities, and high levels of investment in biotechnology and pharmaceutical innovation. The United States, in particular, has been at the forefront of personalized medicine, with many leading biotech and pharmaceutical companies headquartered in the region. These companies are heavily involved in the development and commercialization of personalized gene therapies, with a focus on cancer treatment. Additionally, North America has a robust regulatory framework that supports the approval and widespread adoption of new therapies.

The region also benefits from world-class research institutions and clinical trial centers that are driving innovations in gene therapy. With a large patient population and high demand for cutting-edge cancer treatments, North America remains the dominant region in the personalized gene therapy market. As the market for personalized cancer treatments continues to grow, North America is expected to maintain its leadership role, with ongoing advancements in gene therapy technologies.

Leading Companies and Competitive Landscape

Leading companies in the personalized gene therapy treatments for cancer market include Gilead Sciences, Novartis, Bristol-Myers Squibb, and Bluebird Bio, which are recognized for their pioneering work in gene therapy and cell-based treatments. These companies have developed and commercialized breakthrough therapies, such as CAR-T cell therapies, which have demonstrated remarkable success in treating hematological malignancies. Additionally, emerging biotech companies are focusing on developing next-generation gene therapies for solid tumors, driving further innovation in the market.

The competitive landscape is dynamic, with major players investing heavily in research and development to bring innovative therapies to market. Companies are increasingly partnering with academic institutions, research organizations, and other biotech firms to accelerate the development of personalized gene therapies. As the market grows, the competitive landscape will likely become more fragmented, with both established companies and new entrants vying to bring cutting-edge cancer treatments to patients.

Recent Developments:

• In December 2024, Gilead Sciences announced the launch of a clinical trial for its new personalized gene therapy aimed at treating hematological malignancies using CRISPR technology.
• In November 2024, BioNTech SE revealed its collaboration with a leading research institution to develop gene therapies for solid tumors, marking a significant step toward personalized cancer treatments.
• In October 2024, Kite Pharma expanded its CAR T-cell therapy portfolio with a new product targeting specific genetic mutations in cancers, improving the precision of treatments.
• In September 2024, Sangamo Therapeutics received FDA approval to initiate phase 3 trials for its gene therapy designed to treat inherited forms of blood cancers.
• In August 2024, Medigene AG launched a new gene therapy aimed at improving T-cell efficacy for cancer immunotherapy treatments, focusing on personalized cancer care.

List of Leading Companies:

• Novartis AG
• Gilead Sciences, Inc.
• CRISPR Therapeutics AG
• Editas Medicine
• Kite Pharma (a Gilead Company)
• Intellia Therapeutics
• Sangamo Therapeutics
• BioNTech SE
• Bluebird Bio, Inc.
• Medigene AG
• Moderna Inc.
• Cell Gene Therapy
• TCR2 Therapeutics
• RegenxBio Inc.
• Atara Biotherapeutics

Report Scope: